Recent 8-K filings for EBRCZ

• August 24, 2026, 2:08 PM ET leadership materiality 0.50 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  EBR Systems CCO Erik Strandberg to depart; CEO McCutcheon to lead commercial org

  Chief Commercial Officer Erik Strandberg will leave in coming months; departure not due to any dispute with company.

• August 20, 2026, 3:00 PM ET other material materiality 0.15 neutral item 5.07

  EBR Systems stockholders approve 169.5M CDIs at A$0.38 per CDI, related-party issuance included

  Ratification: 77,352,890 CDIs (7,735,289 shares) at A$0.38/CDI approved with 34.7M for, 485,633 against.

• June 10, 2026, 3:44 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances

  EBR Systems raises A$150M via placement and entitlement offer at A$0.38/CDI

  Total capital raise of A$150M: A$64.4M placement (Tranche 1 & 2) and A$85.6M entitlement offer.

• May 7, 2026, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×9

  EBR Systems shareholders elect directors, approve equity increase and option grants at annual meeting

  Elected John McCutcheon and Bronwyn Evans as Class II directors to hold office until 2029; ~219.3M votes for each.

• April 9, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ

  Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.

• March 26, 2026, 7:59 PM ET other material materiality 0.40 neutral item 5.03item 9.01 ◈ Governance Changes

  EBR Systems announces 1-for-10 reverse stock split effective April 1, 2026

  Board approved 1-for-10 reverse split ratio on March 17, 2026; stockholders authorized ratio range of 1:5 to 1:20.

• March 13, 2026, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  EBR Systems shareholders approve reverse stock split (1:5-1:20) and 55.9M CDI issuance

  Reverse stock split proposal passed with 233.2M for, 970K against; board may set ratio 1:5 to 1:20 or abandon.

• January 13, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  EBR Systems reports Q4 2025 preliminary rev ~$900K; WiSE implants double QoQ, clinical studies advance

  Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).

• May 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  EBR Systems raises ~$36M via 55.9M CDI placement at A$1.00 per CDI

  Issued 55.9M CDIs at A$1.00 (~US$0.6434), raising ~US$36M gross before ~$2.25M fees.

• May 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 3.03item 5.03item 5.07item 9.01 ◈ Governance Changes

  EBR Systems shareholders approve all 11 proposals at 2025 annual meeting, including officer liability amendment

  Re-elected Class I directors Allan Will and Trevor Moody to hold office until 2028 annual meeting.

• April 15, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  CMS proposes NTAP reimbursement for EBR's WiSE CRT at max 65% rate

  CMS proposed NTAP for WiSE CRT System for FY 2026 at maximum add-on payment of 65% of device cost.

• April 14, 2025, 7:59 PM ET regulatory materiality 0.90 positive item 8.01item 9.01

  FDA approves EBR Systems' WiSE CRT System for commercial distribution in US

  FDA approved WiSE CRT System for left ventricular endocardial pacing; target initial US addressable market ~$3.6B.

• March 20, 2025, 7:59 PM ET other materiality 0.25 neutral item 5.03item 9.01 ◈ Governance Changes

  EBR Systems amends bylaws to reduce stockholder quorum from majority to one-third

  Board approved amendment on March 18, 2025, effective immediately.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

4 positive 0 negative 9 neutral

source · EBRCZ on sec.gov